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Abstract
Background: Coronary heart disease (CHD) is the leading cause of death in the developed world, and its prevention
a core activity in current UK general practice. Currently, family history is not systematically integrated into cardiovascular
risk assessment in the UK, Europe or the US. Further, primary health care professionals' lack the confidence to interpret
family history information and there is a low level of recording of family history information in General Practice (GP)
records. Primary prevention of CHD through lifestyle advice has sometimes yielded modest results although, for
example, behavioural interventions targeted at "at risk" patients have produced encouraging findings. A family history
approach, targeted at those requesting CHD assessment, could motivate lifestyle change. The project will assess the
clinical value of incorporating systematic family history information into CHD risk assessment in primary care, from the
perspective of the users of this service, the health care practitioners providing this service, and the National Health
Service.
Methods/Design: The study will include three distinct phases: (1) cross-sectional survey to ascertain baseline
information on current recording of family information; (2) through an exploratory matched-pair cluster randomised
study, with nested qualitative semi-structured interview and focus group study, to assess the impact of systematic family
history recording on participants' and primary care professionals' experience; (3) develop an economic model of the
costs and benefits of incorporating family history into CHD risk assessment.
Discussion: On completion of the project, users and primary care practitioners will be more informed of the value and
utility of including family history in CHD risk assessment. Further, this approach will also act as a model of how familial
risk information can be integrated within mainstream primary care preventive services for common chronic diseases.
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Coronary heart disease (CHD) is the leading cause of
death in the developed world, and its prevention a core
activity in current UK general practice[1]. Family history is
a significant risk factor for CHD, with, for example, 30%
of UK middle-aged men reporting a family history of
CHD experiencing a 71% higher CHD rate over the next
10 years, which remained unchanged after adjusting for
classical risk factors such as cigarette smoking, hyperten-
sion, and obesity[2]. Similar findings have been reported
in the US [3]. European prevention of CHD guidelines
recommend that family history should be used as a pri-
mary prevention approach for CHD[4], while the CDC in
the US has identified CHD as one of five conditions where
identification of familial risk and appropriate interven-
tion could significantly improve health[5]. This initiative
has led to colleagues at the CDC commissioning a multi-
centre clustered randomised controlled trial to evaluate
the utility of a robustly developed CDC family history tool
and intervention software ("Family HealthWare") with
US Primary Care Providers[6]. The tool appears promising
but the trial will not assess the utility of incorporating
family history into standard primary prevention risk
assessment tools.
Currently, family history is not systematically integrated
into CHD risk assessment in the UK, Europe or the
US[1,7]. In the UK, patients who could benefit from pri-
mary prevention of CHD are usually identified using
standard CHD risk assessment scores that incorporate age,
gender, diabetes, smoking status and blood pressure lev-
els[7]. Specifically family history collection should iden-
tify relatives with premature history of CHD. The Joint
British Societies guidelines note that "a family history of
premature CHD (male first degree relatives aged under 55;
female first degree relatives aged under 65) increases the
patient's risk by a factor of approximately 1.5" but this is
not explicitly incorporated in the CHD risk prediction
charts[1]. Our previous research has found that primary
care professionals' lack the confidence to interpret family
history information[8,9] and there is a low level of record-
ing of family history information in General Practice (GP)
records[10].
Primary prevention of CHD through lifestyle advice has
sometimes yielded modest results[11] although, for
example, behavioural interventions targeted at "at risk"
patients have produced encouraging findings[12]. There is
evidence that interventions that have targeted the family
as a whole, rather than individuals, are more effective[13],
and it has been reported that young individuals who were
aware of their family history of CHD were less likely to
smoke[14]. This evidence suggests that a family history
approach, targeted at "at risk" individuals and those
requesting CHD assessment, could motivate lifestyle
change. However, it has been suggested that assessment of
inherited risk may produce fatalism or anxiety[15],
although these findings have not been corroborated in
other studies[16]. Furthermore, people from different
backgrounds have different understanding of the causes of
heart disease; research has also discovered varied "lay
models" of the risk associated with a family history of
heart disease [17-19]. In light of these findings, it has been
emphasized that to be effective, CHD prevention needs
in-depth sensitivity to the ethnically and socioeconomi-
cally diverse patients' personal and cultural models of dis-
ease and family history [17,20]. Still, patients'
interpretations of, and reactions to, incorporating family
history into CHD risk assessment have not been studied.
We have previously explored the psychological impact of
a general family history questionnaire (FHQ)[21] and the
validation of this instrument [22]. We have completed a
qualitative pilot study on the feasibility of incorporating
family history into CHD assessment from a risk commu-
nication point of view [23]. However, in order to inform
policy the assessment of the clinical utility of using family
history is now needed as a priority, alongside work such
as that by the CDC Family HealthWare project, and prior
to the development de novo of further tools[6]. This
should include examination of the behavioural and psy-
chological effects of CHD interventions using family his-
tory assessment. Moreover a better understanding of the
implications of being identified as at higher risk of heart
disease (due to a family history of premature CHD), for
individuals from different social and ethnic backgrounds
is also needed.
The project will assess the clinical value and utility of
incorporating systematised family history information
into Coronary Heart Disease (CHD) risk assessment in
primary care, from the perspective of the users of this serv-
ice, the health care practitioners providing this service,
and the National Health Service. Current CHD risk assess-
ment guidelines express CHD risk within cardiovascular
disease (CVD) risk assessment, with patients divided into
three broad risk categories based on the risk of CVD in the
next 10 years: Average risk (less than 10% CVD risk),
Moderate risk (10% to 19% CVD risk), and High risk
(20% or greater 10 year CVD risk)[1].
This three-phase project will assess the clinical value of
incorporating systematic family history information into
the standard CVD risk assessment in General Practice, by:
1 Estimating the extra proportion of participants at
high risk of CHD, who would benefit from intensive
lifestyle advice and medications, when incorporating
systematically collected family history into the risk
assessment, in comparison with current practice.Page 2 of 10
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iety and social/psychological experience, between
individuals who have been allocated to either CVD
risk assessment using (i) standard risk assessment
complemented by systematic collection of family his-
tory or (ii) standard risk assessment alone (usual care).
Further, there will be an assessment of general practition-
ers' and practice nurses' views on the feasibility and
acceptability of incorporating family history into routine
CVD risk assessment.
To achieve these goals, the project will include three dis-
tinct phases: (1) ascertain baseline information on current
recording of family information, (2) assess, through an
exploratory randomised study (including quantitative
measures, qualitative semi-structured interviews and
focus groups), the impact of systematic family history
recording on participants' and primary care professionals'
experience, and (3) develop an economic model of the
costs and benefits of incorporating family history into
CVD risk assessment. Phase 1 will provide information on
the impact of CHD family history currently available in
GP records on CVD risk assessment, with which the sys-
tematic collection of CHD family history (in Phase 2) will
be compared, to assess the additional value of the latter
intervention. Phase 3 will assess the benefits of systematic
collection through health economic analyses.
Through the above three phases it is anticipated that the
following five outcomes will be evaluated:
Outcome (1)
An estimate of the proportion of the population who are
at a 20% or greater CVD risk in the next 10 years with and
without inclusion of CHD family histories currently col-
lected in GP records. [Phase 1]
Outcome (2)
An estimate of the proportion of the population who are
at a 20% or greater CVD risk in the next 10 years, compar-
ing current practice to systematic collection of family his-
tory in the intervention practices. [Phase 2]
Outcome (3)
A comparison of self-reported behaviour (smoking, exer-
cise, diet), psychological impact (anxiety, fatalism), per-
ception of health, psychological and social experience
between participants who have undergone CVD risk
assessment using (i) standard risk assessment alone or (ii)
standard risk assessment complemented with systematic
collection of family history. [Phase 2]
Outcome (4)
An evaluation of the acceptability and feasibility to gen-
eral practitioners and practice nurses of incorporating for-
mal family history collection into their routine CVD
assessment. [Phase 2]
Outcome (5)
A cost-effectiveness analysis of systematic family history
collection compared to current practice will be under-
taken from an NHS primary care perspective over the trial
period. Parameters for the analysis will come from phase
1 and 2 of the project, supplemented with data from the
published literature where necessary. [Phase 3]
On completion of the project, users and primary care
practitioners will be more informed of the value and util-
ity of including family history in CVD risk assessment.
Further this approach will also act as a model of how
familial risk information can be integrated within main-
stream primary care preventive services for common
chronic diseases.
Method/design and discussion
To achieve the five research outcomes the project will pro-
ceed through three distinct phases. All phases of the study
received ethical approval from the Multi Centre Research
Ethics Committee for Scotland.
PHASE 1: BASELINE CVD RISK ASSESSMENT 
WITH/WITHOUT CURRENTLY AVAILABLE 
INFORMATION ON CHD FAMILY HISTORY 
IN GP RECORDS
During this phase, the inclusion of currently collected
information about family history of premature CHD in
General Practice records on CVD risk assessment will be
assessed. The results of this phase will inform outcome 1.
This entails a cross-sectional survey to examine the current
collection and retrieval of family history data in GP man-
ual records. The impact on absolute CVD risk scores of
premature CHD family history will be informed by con-
sensus. Using GP records, standard CVD risk assessment
will be compared with risk assessment resulting from the
inclusion of previously collected CHD family history in
GP records.
Methods
Consensus agreement
absolute risk of CHD associated with premature CHD in
first and second degree relatives will be identified through
expert panel and literature review using Joint British Soci-
eties' guidelines as a baseline[1]. As well as the project
team, the panel will include the following experts: Cardi-
ovascular epidemiologists [John Yarnell, Queens Univer-
sity Belfast (who has been involved in several prospective
CHD studies and on MONICA projects for CHD), PublicPage 3 of 10
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eral Practitioner with a track record of assessing CHD
genetic morbidity in Primary Care (Dr Ian Hopkinson),
Public health academic with special interest in Genetics
(Brenda Wilson, Ottawa University) and Community
geneticist (Judith Allanson, Ottawa University)].
Outcome measures data collection
Current levels of recording of premature CHD family his-
tory in GP computer records for participants recruited in
Phase 2; supplemented by data from research team's pre-
vious studies, and literature review. The calculation of
CVS risk will follow current JBS 2 guidelines[1].
Outcome measures data interpretation
Calculate current level of recording of relevant CHD fam-
ily histories in GP computer records of participants
entered in phase 2; Establish baseline distribution of
recruited participants with average, moderate or high CVD
risk categories, (less than 10%; 10 to 19%; 20% or greater
CVD risk in next 10 years) on standard CVD risk assess-
ment[1]. Recalculate the proportion at 20% or greater
CVD risk after the inclusion of family history data rou-
tinely collected in GP records.
Sample Size
The proportion of the population at high CVD risk (20%
and greater CVD risk over the next 10 years) has been esti-
mated to be at least 5%[24]. From our previous studies in
which GP records were reviewed, between 3% and 13%
fulfil Joint Society family history guidelines[1]. Based on
this data it is estimated that the proportion of population
at high CVD risk, after the inclusion of previously col-
lected family history in the calculation, will increase by
1% to 6% (in the age group 30 to 65). To estimate an
expected percentage of 6% with a two-sided 95% confi-
dence interval extending from 3.5 to 8.5% a total of 347
participant GP manual records need to be reviewed. The
small anticipated increase acknowledges the poor record-
ing of this information, and the assumption that not all
participants who are actually at higher familial risk will
shift into the high CVD risk category.
PHASE 2: IMPACT AND ACCEPTABILITY OF 
SYSTEMATIC FAMILY HISTORY 
COLLECTION: AN EXPLORATORY 
MATCHED-PAIR CLUSTER RANDOMISED 
STUDY
This phase of the project seeks to evaluate the impact of
systematically collecting relevant premature CHD family
histories. The data collected will be both quantitative, in
terms of the number of extra participants identified and
self-reported behavioural and psychological measures,
and qualitative, in terms of the experience of participants
and professionals involved. The results of this phase will
inform outcomes 2 and 5 and achieve outcomes 3 and 4.
Qualitative interviews will explore the processes that lead
to the quantitative outcomes and evaluate social, cultural,
service-related factors and ethical concerns that affect the
acceptability and effectiveness of the intervention. Quali-
tative research has successfully been incorporated into
randomised studies testing complex behavioural interven-
tions in order to explore the acceptability of the interven-
tion[25] and to examine the psychosocial processes that
lead to the quantitative outcomes[26,27]. Focus groups
will facilitate a participatory dialogue between clinicians
on the acceptability and feasibility of the interven-
tion[28].
Methods
Study Design
A pragmatic exploratory matched-pair cluster randomised
study with a nested qualitative semi-structured interview
and focus group project. Practices from the Trent and
Peninsula research networks will be invited to participate
in the study. Researchers at both sites will visit interested
practices to explain the research project. Twelve pairs of
eligible practices, who agree to participate, will be
recruited (6 pairs from South West England and 6 pairs in
the East Midlands). The practices will be paired according
to level of deprivation (as per Indices of Multiple Depriva-
tion (IMD) quintiles), and ethnicity (as per more or less
than 10% non-White population) in their specific elec-
toral wards. One of each pair will be randomly assigned to
the standard CVD risk assessment procedure, whilst the
other practice within the pair, in addition to providing a
standard CVD risk assessment, will also take account of
premature CHD familial risk using the family history
questionnaire (FHQ). Randomisation will be stratified by
study centre. The matched-paired allocation scheme is
demonstrated in figure 1. The randomisation list will be
prepared centrally by an independent data manager at the
University of Nottingham Clinical Trials Support Unit
(CTSU). The random allocation sequence will be gener-
ated by a computer programme and the treatment alloca-
tion for each practice will be obtained by a password-
protected internet link. The practices, research staff and
participants will not be blinded to group assignment but
the study statistician will be. For the statistical analysis
treatment arms will be distinguished by a code assigned
by the independent data manager at the CTSU. The mean-
ing of these codes will not be revealed to any members of
the research team until data analysis is complete. Figure 1
indicates the matched-pair allocation scheme used in this
study.
The nested qualitative study will recruit participants in
both the intervention and control arms, who have been
assessed to be at high risk of heart disease (20% or above
risk in the next ten years). We expect the impact of thePage 4 of 10
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interviews will yield insights into how participants cope
with being defined as at high risk, what behavioural and
psychological impact this risk information has and how
the response is mediated by individual and social con-
texts. Conducting the interviews with participants in both
intervention and control arms allows for exploring
whether family history assessment renders the partici-
pants' experience different and how.
After the recruitment for the study has been completed, six
practices in the intervention arm (3 in the East Midlands
and 3 in the South West) will be invited for a focus group.
The focus groups will seek to solicit clinicians' views on
the acceptability, feasibility and usefulness of the family
history assessment; it will also invite the clinicians to dis-
cuss their usual practice in terms of taking family history
of heart disease.
Study interventions
FHQ group
Detailed CHD family history information will be col-
lected by participants completing a CHD focused vali-
dated Family History Questionnaire (FHQ) (already
developed and evaluated by the research team)[22]. The
effect of incorporating this information into the standard
CVD risk assessment procedure and the subsequent advice
given to participants on CVD risk and lifestyle will be
assessed.
Control group
Participants will have their CVD risk assessment score cal-
culated using the standard CVD risk assessment proce-
dure.
Details of planned interventions
Participating clinicians in both groups will be given stand-
ardised training, including interpreting CVD risk, stand-
ard evidence/consensus based messages for lifestyle
change. Clinicians in the FHx will in addition, be given
information on interpreting and communication about
the risk associated with family history of premature CHD,
based on our pilot study[23]. To enhance the standardisa-
tion of the training, initial training sessions in both arms
on both study sites will be video recorded, compared and
fed back to the trainers.
Eligibility criteria
The eligibility criteria will ensure the inclusion of multi-
ethnic and socio-economically deprived areas.
Practice level eligibility criteria
Inclusion Criteria
▪ To be within either Trent Primary Care Trusts in Not-
tinghamshire and Lincolnshire or the area served by
the Peninsula Primary Care Research Network in
Devon and Cornwall.
Matched-Pair Allocation SchemeFigur  1
Matched-Pair Allocation Scheme. T = Trent, S = Southwest, Tc = control site in Trent, Sc = control site in Southwest, Ti 
= intervention site in Trent, Si = intervention site in Southwest.
 
2 4  St u dy  Si t es
 
 
 
 
 
St r a t i f i ca t ion  
 
 
 
 
 
 
Mat ch ed  Pai r in g  
 
 
 
 
Ran d om izat ion  
 
 
Con t r o l   
Si t es ( c)   
 
 
 
I n t er v en t ion   
Si t es ( i )   
 
1 2  Sou t h w est  ( S)
2 S2 S 2 S 2 S 2 S 2 S
Sc Sc Sc Sc Sc Sc
Si Si Si Si Si  Si  
1 2  Tr en t  ( T)
2 T 2 T 2 T 2 T 2 T 2 T 
Tc Tc Tc Tc Tc Tc
Ti  Ti  Ti Ti Ti TiPage 5 of 10
(page number not for citation purposes)
BMC Health Services Research 2009, 9:184 http://www.biomedcentral.com/1472-6963/9/184Exclusion Criteria
▪ General Practices outside of these PCTs/networks
will be excluded.
Participant level eligibility criteria
Inclusion criteria
▪ Patients between 30 and 65 years of age.
Exclusion criteria
▪ Patients noted to have a previous history of athero-
sclerotic disease (this includes CHD, CVA & Peripheral
Vascular Disease)
▪ Previous history of Diabetes Mellitus
▪ Patients already on statin therapy or other lipid low-
ering medications
▪ Patients considered by the General Practitioners to be
inappropriate to recruit due to psychosocial and other
reasons.
Recruitment
Patients, who are offered CVD risk assessment and
referred for a cholesterol test as part of their normal care
(either at their doctor's initiative or at their own request),
will be invited to participate. These patients will be
recruited opportunistically, as they present to the GP and
practice nurse for a CVD risk assessment. They will be
given a study pack, which includes consent forms, partic-
ipant information sheet, collection of information on
CHD risk factors (age, gender, ethnicity) and baseline out-
come measures. Participants in the FHQ group will be
given, in addition, the Family History Questionnaire. The
completed baseline questionnaires and consent forms
will be sent to the research team or handed to the practice
receptionist, who will forward them to the research team.
Data collection procedures
After initial recruitment, all participants will have their
medical records reviewed to reconfirm their eligibility. On
arrival of the cholesterol blood results, CVD risk scores
will be calculated by the research team, as per JBS2 guide-
lines[1]. In the FHQ group, familial CHD risk will also be
calculated and incorporated into the overall score. Two
weeks after the original consultation both clinicians and
participants will be sent a letter informing them about the
participant's risk status. Participants identified at average
or moderate CVD risk in both groups will be sent a letter
confirming status together with a leaflet on lifestyle
advice. In addition to a leaflet, those at higher risk in both
groups will be informed that they are at higher than aver-
age CVD risk and invited for a consultation in the practice
within the next 2 weeks.
In the consultation with doctor or nurse, participants will
have their CVD risk explained and given lifestyle advice
and, when clinically indicated, statins will be offered, as
per usual practice. Participants in the FHQ group will also
have the impact of premature CHD family history on the
CVD risk score explained.
At two weeks and six months after the second consulta-
tion (for high risk participants) or letter being sent (for
average or moderate risk participants) all participants will
be posted a set of questionnaires. Participants, who have
been identified at high risk, will be invited for a qualita-
tive interview by phone, following a purposeful, maxi-
mum variation sampling strategy in terms of being in
intervention or control arm, gender, age, occupational
class, ethnicity, region and having or not having a family
history of premature CHD. Recruitment will continue
until thematic saturation is reached. Participants in the
qualitative study will be interviewed by an experienced
researcher in their homes (or if the participants so desire
by phone) at 2 weeks and 6 months after the consultation
in the practice.
Six practices in the intervention arm will be invited to par-
ticipate in a focus group to capture the practitioners' views
on using family history assessment and incorporate this
into their clinical decision making.
After nine months the recruited participants' computer GP
records will be reviewed for prescribing of: lipid lowering,
anti-obesity, and anti-thrombolytic drugs, as well as nico-
tine replacement therapy.
Outcome measures
The primary outcome measure is the proportion of partic-
ipants falling in the high risk of CVD category
The secondary outcome measures are:
i) Self-reported lifestyle changes; including changes in
smoking habits, levels of exercise and fat intake[29,30]
ii): Anxiety, using the 6 item Spielberger State-Trait Anxi-
ety Inventory (STAI)[31] and fatalism and causal attribu-
tions of heart disease using the Illness Perception
Questionnaire[32,33]
iii): Perception of health-related quality of life (SF-6D,
derived from SF-36, and global question 2)[34,35].
The first two groups of these measures have been used in
the assessment of CHD prevention in UK primary care.
Perception of health and 6 item STAI measures have been
used in other studies on family history and genetic screen-
ing in primary care[21,36,37].Page 6 of 10
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tual processes that mediate lifestyle change and risk per-
ceptions of participants identified as at high risk in both
the control and the FHQ group of the study. Participants'
changes in views and their perceptions of heart disease,
family history, their personal risk, lifestyle, medications,
ethical concerns and their social, cultural and familial
context will be collected.
Data management
The FHQs and outcome questionnaires will be ano-
nymised, given a unique identifier and then entered onto
a database. An Access database will be specifically
designed to monitor returns from each participating prac-
tice using consecutive numbering. The identifiable data
will be stored securely at one site and this information
will not be linked to actual socio-economic data, CVD risk
assessment variables, family history and outcome meas-
ures; the unique identifier will be used for this purpose.
The Access administration database will include fields for
age, gender, consent to participate, post code and sub-
sample agreeing to be interviewed. Each week a printout
will be generated providing details of participants who
need to be contacted and sent the postal survey. The
returning data will then be entered onto the main data-
base using the participant's unique identification number.
Quality control in data entry: a 1 in 2 sample of the first
200 lifestyle outcome questionnaires at baseline and 2
weeks will be rechecked to identify errors in entry. Error
rates greater than 0.5% will lead to double checking of all
data entry. All CVD risk assessment scores will be checked
by a second member of the team.
Interview and focus group audiotapes will be transcribed
verbatim (no names or other identifying details will be
included), and stored separately and securely away from
transcripts.
The data will be stored for ten years on completion, in a
locked filing cabinet within the researcher's employing
organisational premises, in accordance with the Sponsor's
requirements. Electronic data will be stored in an ano-
nymised format and will also be encrypted.
All members of the research team will work within the
principles of the Data Protection Act (1998) and Caldicott
and Research Governance.
Sample size
The sample size for the primary outcome measure is based
on the comparison of the change in the percentage of par-
ticipants classified as being at high CVD risk between
treatment groups. The calculation assumes that the pro-
portion of participants at high risk will increase by 3% in
the FHQ group and that there will be no increase in the
standard risk assessment (control) group. Assuming a
power of 80% and a two-tailed alpha of 0.05, 265 partic-
ipants per group are required to detect a difference of 3%.
To allow for the cluster design, an ICC of 0.01 and a clus-
ter size of 40 are assumed. This gives a sample size of 369
participants per group completing CVD risk assessment
(i.e. 10 practices per group). This is a conservative esti-
mate since the increase in precision due to the matching
of practices is not allowed for as it was difficult to find an
estimate of the ICC from matched-pair data.
Further, up to 40 individuals fulfilling the "high risk" cri-
teria, either incorporating or not incorporating family his-
tory, will be invited for qualitative interviews (this will be
sufficient to reach thematic saturation in major sub-
groups). Focus groups will be conducted with clinicians at
six practices in the FHx arm (approximately 35 individu-
als in total), which is also estimated to be sufficient for
thematic saturation.
Attrition rate
One thousand four hundred patients will be invited to
participate. It is estimated that one thousand participants
will complete consent and baseline questionnaire, with
eight hundred completing the CVD risk assessment by
having the serum cholesterol test, resulting in 400 partici-
pants recruited in each arm of the study.
Further, related to secondary outcome measures, it is esti-
mated that 60% of recruited participants will complete
the 6 month questionnaire. Hence 300 participants in
each arm are expected to complete the study.
Data analysis
Quantitative data: Analysis will be undertaken on an
intention to treat basis in that participants will be ana-
lysed in the groups to which they were allocated. The pri-
mary time point of interest is 6 months. Practices will be
included in the analysis provided complete data (the out-
come of interest at baseline and at 6 months follow up,
and participant/practice level data that will be adjusted for
in the analysis) are available for at least one of the partic-
ipants recruited to the practice. Participants within the
practice with incomplete data will be excluded from the
analysis. If data for the secondary outcomes are missing
for the 6 month assessment, a sensitivity analysis will be
performed in which data from the two week assessment
will be carried forward. An analysis assuming the worst
case scenario of the 6 month assessment value being the
same as the baseline value will also be performed.
The distribution of participants in average, moderate and
high risk categories will be described by treatment group.Page 7 of 10
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of CVD in the next 10 years as a result of incorporating
systematically collected family history into CVD risk
assessment score will be presented. For the primary out-
come measure and the secondary outcome measures that
are binary variables, the statistical significance of the dif-
ference in the event rates (e.g. the mean proportion of par-
ticipants at high risk) between the FHQ and control
groups will be calculated using a weighted paired t-test
after the adjustment for the pairing of practices, partici-
pant and practice level variables that are associated with
the outcome of interest. A weighted paired t-test will be
used because it is anticipated that there will be wide vari-
ation in the number of participants recruited per practice.
The robustness of the t-test will be assessed using a permu-
tation test. Continuous outcome variables will be ana-
lysed using a similar method with differences in the mean
response between the FHQ and control groups being
compared using a weighted paired t-test. 95% confidence
intervals will be presented for the intervention effect for
all outcome measures.
Qualitative data: Interviews will be analysed using the
constant comparative method[38]. Identifying emergent
themes and developing the interview schedule and theory
throughout the research process. It is foreseen that the
qualitative project will identify psychosocial process as
well as aspects of the intervention that mediate the sali-
ence of the lifestyle messages, but the open-ended nature
of the interview process is designed to capture other rele-
vant themes that emerge. The coding of the themes will be
facilitated by the use of NVivo qualitative software, the
thematic analysis during the research process and in the
formal coding phase will be inter-rater validated between
experienced qualitative researchers, supplemented by
input from primary care practitioners. The analysis will
also explore differences between participants from the
two arms of the study, and with different socioeconomic
and ethnic background. In the final stage, the qualitative
findings will be triangulated with the quantitative data
(including patient records) to facilitate a deeper interpre-
tation of both data sets. Focus groups will also be analysed
using the constant comparative method as described
above but taking into account the conversational patterns
occurring in the focus groups[28]. The topic guide of the
discussion groups will focus on the feasibility and accept-
ability of the intervention for professionals but is open for
other themes that may emerge.
Ethical considerations
We do not foresee major ethical issues arising from our
study. Filling the FHQ may transiently raise patients' anx-
iety[21], but we are recruiting patients who have either
requested CVD risk assessment themselves or been offered
it by their doctor, so we are not increasing anxiety in a pre-
viously unaware population. We will follow normal ethi-
cal procedures to ensure informed consent,
confidentiality and data protection.
PHASE 3: THE FEASIBILITY OF 
INCORPORATING CHD FAMILY HISTORY 
INTO CHD RISK ASSESSMENT IN PRIMARY 
CARE: AN ECONOMIC PERSPECTIVE
Overview
The resources available to provide health care are limited
and therefore, it is important to establish if incorporating
the systematic family history tool into CVD risk assess-
ments is both effective and cost effective, that is, does the
family history tool offer value for money. This phase will
establish the costs of the intervention and the cost conse-
quences of using the family history tool alongside esti-
mating the benefits of using the tool. Using data from
phases 1 and 2, (and if necessary other published data),
an economic evaluation of the systematic incorporation
of family history into CVD risk assessment compared to
current practice from an NHS primary care perspective
will be undertaken over the trial period. Established and
accepted economic methodologies will be employed
throughout[39]. This phase will achieve outcome 5 of the
study.
Methods
A cost analysis will be undertaken. Resource items likely
to change as a result of the intervention (as well as the cost
of developing and providing the intervention) will be
identified and measured (collected using MIQUEST soft-
ware) during phase 1 and 2. Unit costs will be derived
from national published data[40,41] and used to value
the resources measured for a common price year.
If the family history tool is to improve outcomes it not
only needs to identify more at-risk individuals at an ear-
lier stage (although this is likely to induce some benefit
compared to usual practice in and of itself) but also lead
to behavioural change. Such behavioural change is likely
to take time as people go through stages of change
towards permanent change. Therefore, the six month
period of the trial may only be sufficient to detect the
change in numbers identified rather than any actual
change to health-related quality of life brought about
through behavioural change. To test if this is in fact the
case, two outcomes will be measured and two approaches
to economic evaluation employed. This study will esti-
mate the cost-effectiveness in terms of cost per additional
high risk individual identified and the cost utility using
the SF-6D administered at baseline and 6 months[35] to
estimate the cost per QALY over the trial period (with use
of 2 week score for sensitivity analysis, if 6 month score
not available). Both analyses enable technical efficiency
questions to be addressed, that is how best to identifyPage 8 of 10
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to family history collection or not) whilst the cost-utility
analysis will also enable allocative efficiency questions to
be addressed, that is whether resources spent on using a
systematic approach to CHD family history collection are
considered cost-effective compared to a diverse range of
other health interventions or services.
The timeframe for the economic analysis will be that of
the trial period. If non-dominance occurs (that is if costs
are greater and the intervention is more effective or if the
intervention is cheaper and less effective) an incremental
cost-effectiveness ratio (the ratio of change in cost divided
by change in benefit comparing the systematic approach
to family history collection versus usual care) will be pro-
duced. The confidence region around the incremental cost
effectiveness ratio will be estimated and presented using
appropriate statistical techniques[42]. Appropriate sensi-
tivity analyses will be undertaken to test the robustness of
the results.
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